MIME-Version: 1.0
Server: WebSTAR/2.1 ID/32304
Message-ID: <b0b80f5a.3988@www.epixmed.com>
Date: Sat, 13 Dec 1997 21:41:51 GMT
Last-Modified: Tue, 01 Jul 1997 00:17:28 GMT
Content-type: text/html
Content-length: 3942

<HTML><HEAD>   <TITLE>MS-325</TITLE></HEAD><BODY BGCOLOR="#FFFFFF"><P><CENTER><A NAME="top"></A><IMG SRC="graphics/logo_spacer.gif"WIDTH=113 HEIGHT=50 ALIGN=bottom><IMG SRC="graphics/m325banr.gif"WIDTH=320 HEIGHT=50 ALIGN=bottom><BR><A HREF="index.html"><IMG SRC="graphics/hometabs.gif" ALT="Home"WIDTH=67 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="index2.html"><IMGSRC="graphics/aboutabs.gif" ALT="About EPIX" WIDTH=99 HEIGHT=21BORDER=0 ALIGN=bottom></A><A HREF="ms325.html"><IMGSRC="graphics/m325tabs.gif" ALT="MS-325" WIDTH=76 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="technology.html"><IMGSRC="graphics/techtabs.gif" ALT="Technology R&amp;D" WIDTH=137HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="http://www.prnewswire.com/prn/owa/cn_liststory?id=120427"><IMGSRC="graphics/newstabs.gif" ALT="News" WIDTH=54 HEIGHT=21 BORDER=0ALIGN=bottom></A><BR><A HREF="publications.html"><IMG SRC="graphics/paprtabs.gif"ALT="Publications" WIDTH=109 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="employment.html"><IMGSRC="graphics/jobstabs.gif" ALT="Employment Opportunities" WIDTH=107HEIGHT=21 BORDER=0 ALIGN=bottom></A><A HREF="investor.html"><IMGSRC="graphics/invetabs.gif" ALT="Investor Info" WIDTH=106 HEIGHT=21BORDER=0 ALIGN=bottom></A><A HREF="request.html"><IMGSRC="graphics/datatabs.gif" ALT="Request Information" WIDTH=111HEIGHT=21 BORDER=0 ALIGN=bottom></A></CENTER><H1><HR>Noninvasive Cardiovascular Imaging</H1><P>EPIX Medical, Inc. is developing targeted contrast agents toimprove the capability of <A HREF="m1MRI.html">magnetic resonanceimaging</A> ("MRI") to diagnose a variety of diseases. The Company'sprincipal product under development, MS-325, is an injectablevascular contrast agent. The Company believes that MS-325 willsimplify the diagnostic pathway for a number of diseases and in manycases replace highly invasive and expensive conventional<A HREF="m4xray.html">X-ray angiography</A>. EPIX believes thatMS-325 will significantly enhance the quality of images and providephysicians with a clinically superior, noninvasive and cost-effectivemethod for diagnosing cardiovascular disease.<P><TABLE BORDER=0>   <TR>      <TD>         <P><CENTER><IMG SRC="images/frame1.gif" WIDTH=228 HEIGHT=173         ALIGN=bottom></CENTER>      </TD><TD>         <P><CENTER><IMG SRC="images/frame3.gif" WIDTH=228 HEIGHT=173         ALIGN=bottom></CENTER>      </TD></TR>   <TR>      <TD>         <P><CENTER><B><A HREF="m4xray.html">Conventional X-ray         Angiography</A></B></CENTER>      </TD><TD>         <P><CENTER><B><A HREF="m1MRI.html">Magnetic Resonance         Imaging</A></B></CENTER>      </TD></TR></TABLE><H2><A NAME="EPIX Solution"></A>The EPIX Solution: MRI with MS-325</H2><P>MS-325 is a magnetically active, injectable small molecule. Itbinds to the blood protein albumin, remains at high concentrations inthe bloodstream throughout the MRI exam, and is designed to beexcreted safely through the kidneys over time. Because of itsaffinity for albumin, MS-325 provides the image time and signalstrength needed to obtain a high-contrast, high-resolution image ofthe cardiovascular system.<H1><HR>FAQ's/Topics</H1><BLOCKQUOTE><P><A HREF="m1MRI.html">What is Magnetic ResonanceImaging?</A><P><A HREF="m1MRI.html#contrast agent">What is a contrast agent?</A><P><A HREF="m2cardiology.html">MS-325 Cardiology Indications</A><P><A HREF="m3radiology.html">MS-325 Radiology Indications</A><P><A HREF="m4xray.html">The Current Procedure: X-Ray Angiography</A></BLOCKQUOTE><P><A HREF="#top">Return to top of page.</A><P><CENTER><HR>&copy; 1997, EPIX Medical, Inc.<BR><P><CENTER>E-mail us at<A HREF="mailto:info@epixmed.com">info@epixmed.com</A></CENTER><P><CENTER>&nbsp;</CENTER><P><CENTER>&nbsp;</CENTER></BODY></HTML>